Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate.

Author(s) Cornejo, R.A.Escala; García-Talavera, P.; Martin, M.Navarro; López, B.Pérez; Muñoz, M.García; Alonso, M.Pilar Tama; Hernández, J.J.Cruz
Journal Ann Nucl Med
Date Published 2018 Oct

Large cell neuroendocrine carcinoma of the lung (LCNEC) is a high-grade, poorly differentiated tumor that typically does not express somatostatin receptors. Thus, it does not benefit from treatment with somatostatin analogs and peptide receptor radionuclide therapy (PRRT). The current study objective was to demonstrate that treatment with PRRT may be a valid option in neuroendocrine carcinomas with high expression of somatostatin receptors. This is a case report of a 58-year-old man who was diagnosed with LCNEC and received chemotherapy treatment with little benefit. Extensive hepatic and bone metastasis was detected on In-pentetreotide scintigraphy following high uptake of the radionuclide by the tumors. The patient benefitted from neuroendocrine treatment initially and from lutetium Lu 177 dotatate subsequently. A significant clinical and radiological response was observed, along with an improvement in quality of life. The use of PRRT is a valid alternative to chemotherapy in patients with LCNEC involving the expression of somatostin receptors.

DOI 10.1007/s12149-018-1276-6
Keywords Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Quality of Life; Treatment Outcome
ISSN 1864-6433
Citation Ann Nucl Med. 2018;32(8):568572.

Related Applications, Forms & Industries